VIRIDIAN THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 7Avg age 52Avg tenure 3.3y
SM
Stephen Mahoney
Chief Executive Officer
Age 55Since 2023-10-29Profile →
+11
Executives5
SM
Stephen Mahoney→
Chief Executive Officer
Age 55Since 2023-10-29
SH
Seth Harmon→
Director of Finance/CFO
Age 46Since 2023-09-11
KB
Kirk Bertelsen→
Chief Tech/Sci/R&D Officer
—Since 2023-12-31
KH
Kyle Haraldsen→
Chief Tech/Sci/R&D Officer
—Since 2023-12-31
RT
Radhika Tripuraneni→
Chief Tech/Sci/R&D Officer
Age 46Since 2025-01-31
Board of directors7
AM
Arlene Morris→
Director/Board Member
Age 74Since 2018-01-02
TK
Tomas Kiselak→
Chairman
Age 39Since 2021-05-31
JM
Jennifer Moses→
Director/Board Member
Age 51Since 2021-07-13
SG
Sarah Gheuens→
Director/Board Member
Age 47Since 2023-09-24
SM
Stephen Mahoney→
Director/Board Member
Age 55Since 2023-10-29
CC
Christopher Cain→
Director/Board Member
Age 42Since 2025-03-09
JA
Jeff Ajer→
Director/Board Member
Age 63Since 2025-03-26
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Fidelity Management & Research Co. LLC | 13.93 % | 15,379,377 |
| BlackRock Advisors LLC | 6.143 % | 6,783,461 |
| Bellevue Asset Management AG | 6.091 % | 6,726,144 |
| Paradigm BioCapital Advisors LP | 5.102 % | 5,633,788 |
| Deep Track Capital LP | 4.906 % | 5,417,660 |
Catalog · 2026-07-09
Registry officers12
| Name | Role | Since | Shares |
|---|---|---|---|
| Kirk Bertelsen | Chief Tech/Sci/R&D Officer | 2023-12-31 | - |
| Kyle Haraldsen | Chief Tech/Sci/R&D Officer | 2023-12-31 | - |
| Radhika Tripuraneni | Chief Tech/Sci/R&D Officer | 2025-01-31 | - |
| Seth Harmon | Director of Finance/CFO | 2023-09-11 | - |
| Stephen Mahoney | Chief Executive Officer | 2023-10-29 | - |
| Tomas Kiselak | Chairman | 2021-05-31 | - |
| Arlene Morris | Director/Board Member | 2018-01-02 | - |
| Christopher Cain | Director/Board Member | 2025-03-09 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 36.75Range 22–50Analysts 16
22Mean 36.7550
- Strong buy 3
- Buy 14
Broker actions40 of 131
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | 38 | 2026-09-22 |
| RBC Capital | Maintained | Outperform | 36 | 2026-08-07 |
| Truist Securities | Maintained | Buy | 39 | 2026-08-07 |
| RBC Capital | Maintained | Outperform | 35 | 2026-06-30 |
| Truist Securities | Maintained | Buy | 38 | 2026-06-30 |
| Wedbush | Maintained | Outperform | 43 | 2026-06-30 |
| Needham | Maintained | Buy | 34 | 2026-06-30 |
| Wells Fargo | Upgrade | Overweight | 31 | 2026-06-29 |
| Needham | Reiterated | Buy | 32 | 2026-06-29 |
| Evercore ISI Group | Maintained | Outperform | 26 | 2026-05-15 |
| RBC Capital | Maintained | Outperform | 34 | 2026-05-06 |
| Needham | Reiterated | Buy | 32 | 2026-05-05 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.